This inventor holds 11 USPTO granted patents. Top assignees: National Research Development Corporation, British Technology Group Limited, Warner-Lambert Company. Active years: 1986-1997.
Location History:
- Epsom Downs, GB (1986 - 1988)
- Wheatley, GB (1992 - 1997)
- Didcot, GB (1997)
Company Filing History:
5 out of 1,200 
4 out of 328 
4 out of 2,538 Years Active: 1986-1997
Title: The Innovative Contributions of Gerald E Adams
Introduction
Gerald E Adams is a notable inventor based in Wheatley, GB, recognized for his significant contributions to the field of chemistry and pharmaceuticals. With a total of 11 patents to his name, Adams has made strides in developing compounds that have potential applications in medical treatments.
Latest Patents
Among his latest patents are innovative compounds such as Chiral [(2-bromoethyl)-amino]methyl]-2-nitro-1H-imidazol-1-ethanol and chiral compounds useful as radiosensitizers or chemosensitizers. These compounds are characterized by specific formulas that include halogens and intermediates used in their preparation. Additionally, he has developed a novel process for preparing these compounds, which are aimed at enhancing the efficacy of bioreductive agents in treating solid tumors. This involves administering a nitric oxide (NO) synthase inhibitor alongside an imidazole or 1,2,4-triazole derivative, showcasing his innovative approach to cancer treatment.
Career Highlights
Throughout his career, Gerald E Adams has worked with prominent organizations such as the National Research Development Corporation and the British Technology Group Limited. His work in these institutions has allowed him to advance his research and contribute to the development of new technologies and compounds.
Collaborations
Adams has collaborated with notable colleagues, including Ian J Stratford and Edward M Fielden. These partnerships have likely enriched his research and led to further advancements in his field.
Conclusion
Gerald E Adams stands out as a significant figure in the realm of innovation, particularly in the development of compounds with therapeutic potential. His extensive patent portfolio and collaborative efforts highlight his dedication to advancing medical science.